Result of AGM

RNS Number : 1258R
Microsaic Systems plc
25 June 2020
 

25 June 2020

Microsaic Systems plc

("Microsaic" or the "Company")

Result of AGM

Microsaic Systems plc (AIM:MSYS), the developer of point of need mass spectrometry ("MS") instruments, is pleased to announce that all resolutions proposed at its Annual General Meeting today were duly passed on a poll, the results of which are set out below:

 

 

Ordinary resolutions

Votes

for

% of votes cast

Votes against

% votes cast

Votes withheld

1

To approve the audited accounts of the Company for the year ended on 31 December 2019, together with the Directors' Report and Auditors' Report thereon

329,369,671

100.00

-

-

500

2

To re-appoint Saffery Champness LLP as auditors to the Company, and that the Board be authorised to fix the

remuneration of the auditors

329,176,504

99.94

193,667

0.06

-

3

To re-appoint Bevan Metcalf as a Director of the Company

329,370,171

100.00

-

-

-

4

To authorise the Directors to allot equity securities up to an

aggregate nominal amount of £380,304

329,176,504

99.94

193,667

0.06

-

 

Special resolution

Votes

for

% of votes cast

Votes against

% votes cast

Votes withheld

5

To dis-apply statutory pre-emption rights

328,461,504

99.73

908,667

0.27

-

 

 

Enquiries:

 

Microsaic Systems plc

+44 (0) 1483 751 577

Glenn Tracey, CEO

 

Bevan Metcalf, FD

 

 

N+1 Singer (Nominated Adviser & Joint Broker)

+44 (0)20 7496 3000

Aubrey Powell / George Tzimas (Corporate Finance)

 

Tom Salvesen (Corporate Broking)

 

 

WH Ireland Limited (Joint Broker)

+44 (0)20 7220 1666

James Joyce (Corporate Finance)

 

Jasper Berry (Corporate Broking)

 

 

About Microsaic Systems

Microsaic Systems plc (AIM: MSYS) is a high technology company developing chip-based, bench-top and point-of-analysis mass spectrometry ("MS") instruments that are designed to improve the efficiency of pharmaceutical R&D and manufacturing, and have applications in environmental testing, chemical reaction monitoring, and academic teaching. The Company is working with a range of established global life science OEM partners, distributors and research organisations to co-develop and commercialise new solutions to improve productivity in the development of small molecule and novel biologic (peptides, antibodies) medicines. MS is a powerful method of analysis to enable earlier decision making relating to product identification, purity and bioactivity, and is the analytical technique of choice for biochemists across many industry sectors.

 

Microsaic's core products, the 4500 MiD®, and MiD®ProteinID are robust and compact MS systems, retaining the functionality of larger conventional MS systems, easier to use by non-specialists, consuming less energy and having lower running costs. For more information, please go to www.microsaic.com .

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGFAMITMTBTBAM
UK 100

Latest directors dealings